NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Of course they would allow a trial without crossover—it depends. Not every trial has crossover. It was required for the DCVax GBM P3 trial.

The Keytruda combo trial for rGBM is another example of a trial that might not need a mandated crossover. This very different trial has a placebo group who all have access to DCVax right from the start, so they are getting something proven quite efficacious for rGBM as placebo subjects.

The placebo group is receiving murcidencel as if it were already SOC for rGBM. For rGBM (recurrent) specifically, there is no SOC to extend life, so dosing the placebo group with murcidencel makes sense.

Murcidencel (DCVax-L) is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus murcidencel in combo at UCLA, skip to minute 45:40